Clinical trial · no report yet · Phase 2/Phase 3
INAVO120
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
- NCT04191499 ↗
- Active not recruiting
- Hoffmann-La Roche
- 225 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 114 | |
| YouTube | 59 | |
| Podcasts | 49 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2/Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Cancer
- Interventions
- Inavolisib; Placebo; Palbociclib; Fulvestrant
- Arms
- Inavolisib + Palbociclib + Fulvestrant · Experimental
- Placebo + Palbociclib + Fulvestrant · Placebo comparator
- Enrollment
- 325
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- Hoffmann-La Roche
- Start
- Jan 29, 2020
- Primary completion
- Sep 29, 2023
- Results posted
- Yes
- Registry record
- NCT04191499 · updated Sep 11, 2026
Publications
linked from the registry- Jhaveri KL, Im SA, Saura C, Loibl S, Kalinsky K, Schmid P, Loi S, Thanopoulou E, Shankar N, Jin Y, Stout TJ, Clark TD, Song C, Juric D, Turner NC. Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2025 Jul 10;393(2):151-161. doi: 10.1056/NEJMoa2501796. Epub 2025 May 31. PubMed 40454641
- Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S, Sunpaweravong P, Musolino A, Li H, Zhang Q, Nowecki Z, Leung R, Thanopoulou E, Shankar N, Lei G, Stout TJ, Hutchinson KE, Schutzman JL, Song C, Jhaveri KL. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2024 Oct 31;391(17):1584-1596. doi: 10.1056/NEJMoa2404625. PubMed 39476340